Therefore, to develop a lead compound for lung cancer treatment, we used an FDA-approved drug library with excellent properties and safety measures in places and discovered a hit compound, DES, that inhibits ANO1 and which is currently used as a prostate cancer treatment agent. This evidence concerns the gene ANO1 and prostate carcinoma.